Applicants: Graham P. Allaway et al.

Serial No.: 09/852,238 Filed: May 9, 2001

Page 2

IV. Claims 13-16, drawn to a method of inhibiting HIV-1
 infection;

- V. Claims 17-18, drawn to a non-chemokine agent binding to the chemokine receptor CCR5;
- VI. Claims 19-21 and 25-26, drawn to a molecule binding to the chemokine receptor CCR5 and inhibiting the HIV-1 binding to CD4 cells, which is linked to a ligand of antibody;
- VII. Claims 22-24 and 25-26, drawn to a molecule binding to molecule binding to chemokine receptor inhibiting HIV-1 binding to CD4 cells, which is linked to a compound to increase the half-life of non-chemokine agent;
- VIII.Claims 27-30, drawn to a method of determining a non-chemokine agent;
- IX. Claims 31 and 33, drawn to transgenic non-human animal comprising an isolated DNA molecule encoding a chemokine receptor;
- X. Claims 32 and 34, drawn to a non-human animal comprising an isolated DNA molecule encoding a portion of CD4 receptor;
- XI. Claim 35, drawn to a transformed cell comprising a nucleic acid molecule encoding chemokine receptor CCR5;
- XII. Claims 36-42 and 47-48, drawn to an agent and a method of using the agent that inhibits HIV-1 infection;
- XIII.Claim 43, drawn to a method inhibiting HIV-1 infection; and
- XIV. Claims 44-46 and 47-48, drawn to a molecule and a method of

Applicants:

Graham P. Allaway et al.

Serial No.:

09/852,238 May 9, 2001

Filed: Page 3

using the molecule, which binds to chemokine receptor CCR5 and is linked to a polyethylene glycol.

The Examiner also stated that upon election of Group XII, a further restriction is imposed under 35 U.S.C. 121, whereby applicant is additionally required to elect a single agent from (1) an oligopeptide, (2) a nonpeptide agent, and (3) a polypeptide.

In response to this restriction requirement, applicants note that a Preliminary Amendment was filed in connection with the subject application on May 9, 2001, canceling claims 1-48 and adding new claims 49-55. Pursuant to a request from Examiner Bao Qun Li during a June 10, 2004 telephone conference with Ashton J. Delauney, Esq., applicants submit herewith as Exhibit A a copy of the May 9, 2001 Preliminary Amendment in lieu of electing one of the fourteen groups presented by the Examiner as representing separate inventions. The undersigned attorney understands that, upon receipt of and satisfaction with this submission, Examiner Li will vacate the June 3, 2004 Office Action imposing a restriction requirement. Applicants note that upon entry of the May 9, 2001 Preliminary Amendment claims 49-55 will be pending.

Applicants also attach hereto as **Exhibit B** a copy of the postcard which accompanied the May 9, 2001 Preliminary Amendment and was returned to applicants' representatives by the Patent Office. The postcard indicates receipt of the Preliminary Amendment by the Patent Office, as evidenced by the Patent Office's stamp bearing the May 9, 2001 date.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants:

Graham P. Allaway et al.

Serial No.: Filed:

09/852,238 May 9, 2001

Page 4

No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

John P. White

Reg. No. 28,678

White John F.

Registration No. 28,678 Attorney for Applicants Cooper & Dunham, LLP

1185 Avenue of the Americas New York, New York 10036

(212) 278-0400